Loading...

GTBP GT BIOPHARMA INC Capital Structure Changes 8-K Filing

GT B

GTBP

GT BIOPHARMA INC

(GTBP)

2025 8-K

Delisting Notice

Financial Results Released

Preferred Stock Waiver

Stockholder Waiver

CEO Employment Renewal

Equity Offerings

Equity Offerings

Equity Offerings

Warrant Issuance

Warrant Inducement

First Patient Dosed

Nasdaq Compliance

Clinical Trial Agreement

Management Change

FDA Clearance of IND Applic...

Annual Meeting Vote Results

Management Change

Purchase Agreement and Priv...

Amendment to Settlement and...

Reverse Stock Split

Special Meeting of Stockhol...

IND Application for GTB-3650

Notice of Delisting

Departure and Appointment o...

Purchase Agreement

External Links:

On September 25, 2025, GT Biopharma, Inc. announced that holders of its Series L 10% Convertible Preferred Stock agreed to waive redemption rights outlined in their Certificate of Designation, following similar waivers from September 17, 18, and 23, 2025.

AI Assistant

GT BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.